https://news.medxy.ai/zh/global-car-t-access-inequality/Medxy AIzh2026-04-11T21:07:00-07:00全球CAR-T细胞疗法获取不平等：健康技术评估分析显示仅一半G20国家推荐报销 https://news.medxy.ai/ja/g20-car-t-access-imbalance/Medxy AIja2026-04-11T21:03:40-07:00G20各国CAR T細胞療法アクセスの不均衡：HTA分析では半数の国のみが償還を推奨 https://news.medxy.ai/vi/global-car-t-therapy-access/Medxy AIvi2026-04-11T21:01:12-07:00Sự khác biệt toàn cầu trong việc tiếp cận liệu pháp CAR T tế bào: Phân tích HTA cho thấy chỉ có một nửa số quốc gia G20 khuyến nghị bồi thường https://news.medxy.ai/global-car-t-cell-access/Medxy AIen2026-04-11T20:56:16-07:00Global Disparities in CAR T-Cell Access: HTA Analysis Reveals Only Half of G20 Countries Recommend Reimbursement https://news.medxy.ai/zh/eosinophil-count-copd/Medxy AIzh2026-04-11T20:06:59-07:00COPD急性加重期的嗜酸性粒细胞计数预测长期心血管风险：一项回顾性队列研究 https://news.medxy.ai/ja/eosinophil-count-copd-risk/Medxy AIja2026-04-11T20:03:37-07:00COPD急性加重期的嗜酸性粒细胞计数预测长期心血管风险：一项回顾性队列研究 https://news.medxy.ai/vi/eosinophil-copd-cardiac-risk/Medxy AIvi2026-04-11T20:00:52-07:00Số lượng Eosinophil trong máu ở bệnh nhân COPD trong giai đoạn bùng phát dự đoán nguy cơ tim mạch dài hạn: Một nghiên cứu hồi cứu trên nhóm đối tượng https://news.medxy.ai/blood-eosinophil-count-copd/Medxy AIen2026-04-11T19:56:23-07:00Blood Eosinophil Count at COPD Exacerbation Predicts Long-Term Cardiovascular Risk: A Retrospective Cohort Study https://news.medxy.ai/zh/challenge-hypothesis-geographic-atrophy/Medxy AIzh2026-04-11T15:44:42-07:00挑战假设：地理萎缩进展中的对侧眼相关性最多只是适度 https://news.medxy.ai/ja/challenge-premise-geographic-atrophy/Medxy AIja2026-04-11T15:43:41-07:00前提に挑戦：加齢黄斑変性症の地理的萎縮進行における対眼相関は、最高でも控えめ https://news.medxy.ai/vi/challenge-assumption-geographic-atrophy/Medxy AIvi2026-04-11T15:41:54-07:00Thách thức Giả định: Mối Liên hệ giữa Các Mắt Đối diện trong Tiến trình Atrophy Địa lý chỉ ở mức Tốt nhất https://news.medxy.ai/fellow-eye-correlations-geographic-atrophy/Medxy AIen2026-04-11T15:39:21-07:00Challenging the Assumption: Fellow-Eye Correlations in Geographic Atrophy Progression Prove Modest at Best https://news.medxy.ai/zh/diabetic-retinopathy-risk/Medxy AIzh2026-04-11T15:28:31-07:00糖尿病视网膜病变严重程度预测死亡风险：来自SOURCE联盟的洞见 https://news.medxy.ai/ja/diabetic-retinopathy-mortality-risk/Medxy AIja2026-04-11T15:27:27-07:00糖尿病性網膜症の重症度が死亡リスクを予測：SOURCEコンソーシアムからの洞察 https://news.medxy.ai/vi/eye-disease-mortality-risk/Medxy AIvi2026-04-11T15:24:48-07:00Độ Nghiêm Trọng của Bệnh Đau Mắt Đường Huyết Dự Đoán Nguy Cơ Tử Vong: Những Hiểu Biết từ Liên Minh SOURCE https://news.medxy.ai/diabetic-retinopathy-mortality/Medxy AIen2026-04-11T15:21:21-07:00Diabetic Retinopathy Severity Predicts Mortality Risk: Insights from the SOURCE Consortium https://news.medxy.ai/determinants-circulating-hpv-dna/Medxy AIen2026-04-11T15:10:42-07:00Determinants of Circulating Tumor HPV DNA in Surgically Treated Oropharyngeal Cancer https://news.medxy.ai/zh/robotics-laparoscopic-cholecystectomy/Medxy AIzh2026-04-10T20:06:02-07:00机器人与腹腔镜胆囊切除术：在不同疾病严重程度下无结果优势 https://news.medxy.ai/ja/robot-surgery-cholecystectomy/Medxy AIja2026-04-10T20:04:31-07:00ロボット手術と腹腔鏡手術の胆嚢摘出術: 病状の重症度に関わらず治療成績に差なし https://news.medxy.ai/vi/robot-vs-laparoscopic-cholecystectomy/Medxy AIvi2026-04-10T20:02:44-07:00Phẫu thuật robot so với phẫu thuật nội soi cắt túi mật: Không có lợi thế kết quả qua các mức độ nghiêm trọng của bệnh https://news.medxy.ai/robotic-vs-laparoscopic-cholecystectomy/Medxy AIen2026-04-10T19:59:11-07:00Robotic vs Laparoscopic Cholecystectomy: No Outcome Advantage Across Disease Severity Grades